Exagen Inc.
XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lā¦ read more
Healthcare
Diagnostics & Research
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.49
Price+1.55%
$0.14
1Y
Price
Market Cap
$208.814m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$58.862m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$16.980m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.89
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$21.034m
$58.760m
Assets$37.726m
Liabilities$2.894m
DebtDebt to Assets
4.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$15.984m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company